Arch Biopartners Stock Buy Hold or Sell Recommendation
| ARCH Stock | CAD 1.95 0.01 0.51% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Arch Biopartners is 'Strong Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Arch Biopartners given historical horizon and risk tolerance towards Arch Biopartners. When Macroaxis issues a 'buy' or 'sell' recommendation for Arch Biopartners, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Arch Biopartners Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Arch and provide practical buy, sell, or hold advice based on investors' constraints. Arch Biopartners. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Arch |
Execute Arch Biopartners Buy or Sell Advice
The Arch recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Arch Biopartners. Macroaxis does not own or have any residual interests in Arch Biopartners or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Arch Biopartners' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Good | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Arch Biopartners Trading Alerts and Improvement Suggestions
| Arch Biopartners may become a speculative penny stock | |
| Arch Biopartners has accumulated 5.02 M in total debt. Arch Biopartners has a current ratio of 0.31, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Arch Biopartners until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Biopartners' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Biopartners sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Biopartners' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 1.98 M. Net Loss for the year was (3.33 M) with loss before overhead, payroll, taxes, and interest of (502.88 K). | |
| Arch Biopartners has accumulated about 72.82 K in cash with (234.07 K) of positive cash flow from operations. | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury - Yahoo Finance |
Arch Biopartners Returns Distribution Density
The distribution of Arch Biopartners' historical returns is an attempt to chart the uncertainty of Arch Biopartners' future price movements. The chart of the probability distribution of Arch Biopartners daily returns describes the distribution of returns around its average expected value. We use Arch Biopartners price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Arch Biopartners returns is essential to provide solid investment advice for Arch Biopartners.
| Mean Return | 0.51 | Value At Risk | -3.43 | Potential Upside | 5.33 | Standard Deviation | 2.68 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Arch Biopartners historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Arch Biopartners Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 253.3K | (205.4K) | 58.1K | 324.9K | 373.7K | 392.3K | |
| Free Cash Flow | (1.9M) | (3.0M) | (1.1M) | (234.1K) | (210.7K) | (221.2K) | |
| Other Non Cash Items | 996.7K | (1.9M) | (25.0K) | 1.1M | 1.3M | 1.4M | |
| Net Income | (4.6M) | (1.2M) | (1.1M) | (3.3M) | (3.0M) | (2.8M) | |
| End Period Cash Flow | 653.7K | 448.2K | 506.3K | 831.3K | 956.0K | 1.0M | |
| Net Borrowings | 1.4M | 488K | 1.7M | (791.3K) | (910.0K) | (864.5K) | |
| Change To Netincome | 288.1K | 2.7M | (1.8M) | 1.9M | 2.2M | 2.3M |
Arch Biopartners Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Arch Biopartners or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Arch Biopartners' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Arch stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.46 | |
β | Beta against Dow Jones | 0.26 | |
σ | Overall volatility | 2.69 | |
Ir | Information ratio | 0.14 |
Arch Biopartners Volatility Alert
Arch Biopartners currently demonstrates below-average downside deviation. It has Information Ratio of 0.14 and Jensen Alpha of 0.46. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Arch Biopartners' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Arch Biopartners' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Arch Biopartners Fundamentals Vs Peers
Comparing Arch Biopartners' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Arch Biopartners' direct or indirect competition across all of the common fundamentals between Arch Biopartners and the related equities. This way, we can detect undervalued stocks with similar characteristics as Arch Biopartners or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Arch Biopartners' fundamental indicators could also be used in its relative valuation, which is a method of valuing Arch Biopartners by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Arch Biopartners to competition |
| Fundamentals | Arch Biopartners | Peer Average |
| Return On Asset | -0.81 | -0.14 |
| Profit Margin | (1.86) % | (1.27) % |
| Operating Margin | (1.39) % | (5.51) % |
| Current Valuation | 132.23 M | 16.62 B |
| Shares Outstanding | 64.94 M | 571.82 M |
| Shares Owned By Insiders | 19.86 % | 10.09 % |
| Number Of Shares Shorted | 3.97 K | 4.71 M |
| Price To Sales | 91.52 X | 11.42 X |
| Revenue | 1.98 M | 9.43 B |
| Gross Profit | (502.88 K) | 27.38 B |
| EBITDA | (5.24 M) | 3.9 B |
| Net Income | (3.33 M) | 570.98 M |
| Cash And Equivalents | 72.82 K | 2.7 B |
| Total Debt | 5.02 M | 5.32 B |
| Current Ratio | 0.32 X | 2.16 X |
| Book Value Per Share | (0.10) X | 1.93 K |
| Cash Flow From Operations | (234.07 K) | 971.22 M |
| Short Ratio | 0.29 X | 4.00 X |
| Earnings Per Share | (0.03) X | 3.12 X |
| Beta | 1.39 | -0.15 |
| Market Capitalization | 129.88 M | 19.03 B |
| Total Asset | 1.17 M | 29.47 B |
| Retained Earnings | (28.05 M) | 9.33 B |
| Working Capital | (4.81 M) | 1.48 B |
| Net Asset | 1.17 M |
Arch Biopartners Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Arch . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Arch Biopartners Buy or Sell Advice
When is the right time to buy or sell Arch Biopartners? Buying financial instruments such as Arch Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Arch Biopartners in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Goods Thematic Idea Now
Consumer Goods
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Consumer Goods theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Goods Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Arch Stock Analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.